8 completed, 7 unknown, 6 recruiting, 3 terminated. 27 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 27 | Completed 8, Unknown 7, Recruiting 6, Terminated 3, Not yet recruiting 2, Withdrawn 1 |
Follow Heart Failure With Preserved Ejection Fraction: new trials by email Literature Review of Heart Failure With Preserved Ejection Fraction trials Research Report on Heart Failure With Preserved Ejection Fraction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IV Iron Therapy for Older Adults With Heart Failure With Preserved Ejection Fraction and Iron Deficiency Ferric derisomaltose, Placebo (normal saline) - Heart Failure With Preserved Ejection Fraction, Iron Deficiency | Phase 4 | Not yet recruiting | Duke University | 300 | 2026-11-01 | 2026-10-15 |
| Finerenone and Cardiac Remodeling in HFpEF Finerenone, Standard of care for HFpEF Description: - Heart Failure With Preserved Ejection Fraction | Phase 4 | Not yet recruiting | Assiut University | 194 | 2026-09-20 | 2026-09-22 |
| Neprilysin Inhibition to Reduce Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction Sacubitril-valsartan, Valsartan - Heart Failure With Preserved Ejection Fraction, Myocardial Fibrosis | Phase 4 | Withdrawn | Brigham and Women's Hospital | 2026-08-27 | 2026-08-31 | |
| Incretin Therapies in Obesity-related HFpEF Tirzepatide - Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction | Phase 4 | Recruiting | Columbia University | 50 | 2026-08-07 | 2026-08-24 |
| SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF Dapagliflozin tablet, Hypertonic Saline Solution, 1 Ml, Furosemide Injection - Heart Failure Acute, Diabetes Type 2 | Phase 4 | Unknown | University of Palermo | 544 | 2024-06-01 | 2024-06-06 |
| EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease Empagliflozin 25 MG, Placebo - Heart Failure With Preserved Ejection Fraction, End Stage Renal Disease on Dialysis | Phase 4 | Recruiting | National Taiwan University Hospital | 150 | 2024-03-05 | 2024-12-16 |
| Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation Sacubitril-valsartan, Standard of care - Heart Failure With Preserved Ejection Fraction, Functional Mitral Regurgitation | Phase 4 | Completed | Ziekenhuis Oost-Limburg | 84 | 2024-02-29 | 2026-06-08 |
| A Preliminary Study for INFORMED Beta blocker - Heart Failure, Heart Failure, Diastolic | Phase 4 | Recruiting | Weill Medical College of Cornell University | 18 | 2024-02-07 | 2026-08-21 |
| The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life Ferric derisomaltose, Placebo - Heart Failure With Preserved Ejection Fraction, Iron Deficiencies | Phase 4 | Recruiting | China-Japan Friendship Hospital | 170 | 2023-08-01 | 2026-11-06 |
| Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants Pioglitazone, Placebo - Type 2 Diabetes Mellitus in Obese, Heart Failure With Preserved Ejection Fraction | Phase 4 | Recruiting | The University of Texas Health Science Center at San Antonio | 78 | 2023-07-10 | 2026-09-22 |
| CAtheter-Based Ablation of Atrial Fibrillation Compared to Conventional Treatment in Patients With Heart Failure With Preserved Ejection Fraction CE-marked Catheter Ablation - Atrial Fibrillation, Heart Failure With Preserved Ejection Fraction | Phase 4 | Recruiting | Charite University, Berlin, Germany | 1548 | 2023-03-01 | 2023-03-06 |
| Empagliflozin for Peripheral Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction Participants receive 10mg Empaglifozin once daily on prescription from their treating physician. This is not an intervention in this trial, but part of their normal HFpEF treatment - Heart Failure With Preserved Ejection Fraction, Microvascular Dysfunction | Phase 4 | Unknown | Maastricht University Medical Center | 48 | 2023-02-13 | 2023-09-21 |
| EMPAGUM: Effects of Empagliflozin on Gut Microbiota in Heart Failure With a Preserved Ejection Fraction Empagliflozin 10 Mg - Heart Failure, Heart Failure With Preserved Ejection Fraction | Phase 4 | Unknown | Zhijun Sun | 100 | 2022-12-15 | 2022-12-23 |
| Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection Fraction Empagliflozin 10 MG - Heart Failure, Heart Failure With Preserved Ejection Fraction | Phase 4 | Unknown | Zhijun Sun | 100 | 2022-11-05 | 2023-03-07 |
| Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients Sotagliflozin, Placebo - Heart Failure With Preserved Ejection Fraction | Phase 4 | Completed | Juan Badimon | 88 | 2022-10-26 | 2026-06-24 |
| Polydiuretic Therapy for HFpEF, a Randomised Controlled Trial Low dose combination polydiuretic therapy, Comparator monotherapy empagliflozin - Heart Failure With Preserved Ejection Fraction | Phase 4 | Terminated | The George Institute | 3 | 2022-10-01 | 2024-11-21 |
| Use of SGLT2i in noHCM With HFpEF Empagliflozin 10 MG - Hypertrophic Cardiomyopathy, Heart Failure With Preserved Ejection Fraction | Phase 4 | Unknown | China National Center for Cardiovascular Diseases | 94 | 2022-08-01 | 2024-05-06 |
| BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in HFpEF Amlodipine Besylate, Metoprolol Succinate - Heart Failure With Preserved Ejection Fraction, Hypertension | Phase 4 | Completed | University of Pennsylvania | 50 | 2021-12-01 | 2026-01-30 |
| Carvedilol in HF With Preserved EF Carvedilol, Placebo - Heart Failure With Preserved Ejection Fraction, Beta Blocker | Phase 4 | Completed | Seoul National University Bundang Hospital | 63 | 2021-11-17 | 2026-05-19 |
| Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection Fraction Empagliflozin 10 MG - Heart Failure with Preserved Ejection Fraction, Heart Failure, Diastolic | Phase 4 | Completed | University of Texas Southwestern Medical Center | 8 | 2021-11-09 | 2024-09-19 |
Showing 20 of 27. Sign in to see all of them.
Heart Failure (10) · Heart Failure, Diastolic (8) · Heart Diseases (3) · Diabetes Mellitus (2) · Diabetes Mellitus, Type 2 (2) · Hypertension, Pulmonary (2) · Iron Deficiencies (2) · Atrial Fibrillation (1) · Cardiomyopathy, Hypertrophic (1) · Hypertension (1) · Kidney Failure, Chronic (1) · Motor Activity (1) · Obesity (1)
Cardiovascular Diseases (16) · Heart Diseases (12) · Nutritional and Metabolic Diseases (6) · Metabolic Diseases (5) · Heart Failure (4) · Endocrine System Diseases (3) · Glucose Metabolism Disorders (3) · Pathological Conditions, Signs and Symptoms (3) · Vascular Diseases (3) · Hypertension (2) · Iron Metabolism Disorders (2) · Lung Diseases (2) · Pathologic Processes (2) · Respiratory Tract Diseases (2) · Aortic Stenosis, Subvalvular (1)
empagliflozin (7) · Adrenergic beta-Antagonists (3) · Carvedilol (3) · Metoprolol (3) · Nebivolol (3) · sacubitril and valsartan sodium hydrate drug combination (3) · Acebutolol (2) · Atenolol (2) · Betaxolol (2) · Bisoprolol (2) · Labetalol (2) · Nadolol (2) · Penbutolol (2) · Pindolol (2) · Propranolol (2)
Weill Medical College of Cornell University (3) · University of Texas Southwestern Medical Center (2) · Zhijun Sun (2) · Assiut University (1) · Brigham and Women's Hospital (1) · Charite University, Berlin, Germany (1) · China National Center for Cardiovascular Diseases (1) · China-Japan Friendship Hospital (1) · Columbia University (1) · Duke University (1) · Hospital General Universitario Gregorio MaraƱon (1) · Juan Badimon (1) · Maastricht University Medical Center (1) · Mayo Clinic (1) · National Taiwan University Hospital (1)
United States (12) · China (4) · South Korea (2) · Australia (1) · Belgium (1) · Germany (1) · Netherlands (1) · Spain (1) · Taiwan (1)
Parag Goyal, MD (2) · Abdul Parwani, Dr. (1) · Ahmed A Ahmed, prof (1) · Burkert Pieske, Prof. Dr. (1) · Carlos G Santos-Gallego, MD (1) · Chih-Cheng Wu, MD. PhD (1) · Clare Arnott (1) · Dong-Ju Choi, MD, PhD (1) · Donna SH Lin, MD (1) · Elissa A Driggin, MD (1) · Fernando Torres, MD (1) · Giuseppe Miceli, PhD (1) · Javier Bermejo Thomas, MD, PhD (1) · Juan J Badimon (1)
PMID 15963399, PMID 20607462, PMID 21329845, PMID 21440872, PMID 21885793, PMID 22980301, PMID 22983988, PMID 23743396, PMID 26240596, PMID 26378978, PMID 28402411, PMID 29724346, PMID 31540679, PMID 32139695, PMID 32709292, PMID 32970396, PMID 34447992, PMID 35241246, PMID 36607775, PMID 37318685, PMID 38737708, PMID 40281528, PMID 40855136, PMID 42104906, PMID 42137945
K76AG064428 (2), 2019 (1), K23GM112014 (1), K23HL168163 (1), R01AG097715 (1), R21AG053512 (1)